GlassScriptPhysician profile
Abdulhadi Quadri
NPI 1811981913
$1,194.16
in general payments reported to CMS, 2019-2025
13 companies · $948 in 2025
The $948 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.00 · 2022: $99.64 · 2024: $117 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $755 · Food and Beverage: $259 · Education: $51.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $754.93 |
| Food and Beverage | $258.50 |
| Education | $51.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ovesco Endoscopy USA, INC. | $754.93 | 2025 | |
| Abbvie INC. | $123.58 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $73.79 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $49.27 | 2025 | Wegovy, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.65 | 2024 | Xifaxan |
| Lilly USA, LLC | $30.60 | 2024-2025 | Omvoh, Zepbound |
| Olympus America INC. | $19.55 | 2025 | Endoclot Phs |
| Celltrion USA INC. | $18.82 | 2024 | Zymfentra |
| Regeneron Healthcare Solutions, INC. | $18.75 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $16.17 | 2024 | Verquvo |
| Celgene Corporation | $13.38 | 2022 | |
| Janssen Biotech, INC. | $13.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdulhadi Quadri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.